Showing 361-370 of 10581 results for "".
How To Fix a Broken Mental Health Care System: Lessons from Virginia Tech
https://reachmd.com/programs/clinicians-roundtable/how-to-fix-a-broken-mental-health-care-system-lessons-from-virginia-tech/514/A disturbed violent young man was repeatedly identified as someone who desperately needed help. Yet he never got that help, and the Virginia Tech tragedy was the result. What does that tell us about our mental health system? And How can it be fixed? Andrew Sperling of the National Alliance on MentalTROP2 ADCs for Metastatic NSCLC: Setting the Stage for Future Use
https://reachmd.com/programs/cme/trop2-adcs-for-metastatic-nsclc-setting-the-stage-for-future-use/14416/Are you as excited as we are to see how TROP2-targeted antibody-drug conjugates can help our patients?Innovations in Precision Medicine: Leveraging Guideline-Based Immunotherapy and Targeted Treatments in Gynecologic Oncology
https://reachmd.com/programs/cme/Innovations-in-Precision-Medicine-Leveraging-Guideline-Based-Immunotherapy-and-Targeted-Treatments-in-Gynecologic-Oncology/37235/Multidisciplinary experts explore biomarker-driven strategies, immunotherapy, and personalized care in cervical and endometrial cancer management.Hi-Lo Phaco: Settings and Details
https://reachmd.com/programs/cme/hi-lo-phaco-settings-and-details/33179/Learn how to fine-tune phaco settings in Venturi and peristaltic modes to enhance chamber stability and efficiency in cataract surgery.Leveraging CGM to Its Full Potential in People with T2D
https://reachmd.com/programs/cme/cgm-full-potential-t2d/50980/Continuous glucose monitoring (CGM) has been widely used in individuals with type 1 diabetes (T1D), and evolving guidelines increasingly recommend its use for those with type 2 diabetes (T2D) as well. However, despite these updated recommendations, real-world adoption to support T2D management has rFrom Diagnosis to Prognosis: Using MyPath® Melanoma and DecisionDx®-Melanoma to Help Guide Patient Management Decisions
https://reachmd.com/programs/practical-dermatology/from-diagnosis-to-prognosis-using-mypath-melanoma-and-decisiondx-melanoma-to-help-guide-patient-management-decisions/39944/Gene Expression Profile Testing Helps Clinicians Clarify Diagnostically Ambiguous Lesions and Deliver Personalized, Risk-Aligned Melanoma CareMeasuring Your Cost Per Lead: It’s So 2019
https://reachmd.com/topics/practice-development/measuring-your-cost-per-lead-its-so-2019/35167/How to assign truly meaningful data about the cost of each bookingBeyond Steroidal MRAs: The Nonsteroidal MRA Lens in HF
https://reachmd.com/programs/cme/beyond-steroidal-mras-the-nonsteroidal-mra-lens-in-hf/49198/Examine how nonsteroidal MRAs inform risk-based treatment in HFpEF and HFmrEF, including stable patients with ongoing cardio-kidney-metabolic risk.Special Report: Management Considerations and Unmet Needs in LGS and Dravet Syndrome
https://reachmd.com/programs/cme/special-report-management-considerations-and-unmet-needs-in-lgs-and-dravet-syndrome/15112/Find out how you can manage polypharmacy in Lennox-Gastaut syndrome and Dravet syndrome and learn what new therapies are on the horizon.Refining First-Line Therapy in Advanced Endometrial Care: LEAP-001 Trial Results
https://reachmd.com/programs/project-oncology/refining-first-line-therapy-in-advanced-endometrial-care-leap-001-trial-results/35507/To explore a potential alternative to chemotherapy, the ENGOT-en9/LEAP-001 trial compared lenvatinib/pembrolizumab to standard chemotherapy in patients with advanced or recurrent endometrial cancer. Learn how these results may shape biomarker-driven approaches and patient selection in frontline endo